Operational updates
Pharming Group and Sanofi renew strategic manufacturing partnership agreement
Pharming announces that it has renewed its strategic manufacturing partnership with long-term manufacturing partner Sanofi S.A. The extended 5-year contract which includes options for extensions, ensures the continuation of the downstream processing in the production of RUCONEST®, a recombinant C1 inhibitor product approved for the acute treatment of hereditary angioedema.
"As a result of this renewed manufacturing partnership, we can now fully focus on our core competencies; the development and commercialization of our products and pursuing additional near-term growthopportunities through in-licensing or acquisition."
- Sijmen de Vries - CEO